- slider1.jpg
- slider1.jpg
TREATING DEADLY INFLAMMATION
CytoSorb® is a unique blood purification therapy to control deadly inflammation in life threatening illnesses in the ICU and cardiac surgery. The product is currently approved in the European Union and distributed in 53 countries around the world.
THE POWER OF THE BEAD
Powered by massive surface area, our purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
INFORMATION FOR INVESTORS
CytoSorbents is a leader in critical care immunotherapy. The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders.
Recent News
- CytoSorbents Issues Stockholder Letter with Preliminary 2018 Financial Results
- CytoSorbents To Highlight Progress at Biotech Showcase 2019
- CytoSorbents To Receive $619,546 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program
- CytoSorbents to Present at the 30th Annual Piper Jaffray Healthcare Conference
- CytoSorbents Recognized Again as One of the Fastest Growing Companies in North America on Deloitte’s 2018 Technology Fast 500™
Videos to Watch On The Street - "Cytosorbents CEO on How to Avoid the Flu
and Cytokine Storms" click here
- slider1.jpg
